Company Profile
Updated: 17-SEP-09Porter, Le Vay and Rose Inc.
Private Company, Headquarters Location
7 Penn Plz., Ste. 810, New York, NY 10001-0011, United States
(212)564-4700, (212)244-3075 fax, http://www.plrinvest.com
Primary SIC: Public Relations Services, Primary NAICS: Public Relations Services
Description: Services: Public relations firm.
View this company profile - Now for a Limited Time, try Goliath Company Profiles
Free for 3 Days!
Neurobiological Technologies Announces Departure of Jonathan Wolter as Vice President and Chief Financial Officer.
PR Newswire; 6/15/2006; 751 words; ...Neurobiological Technologies, Inc. (NTI(R)) today announced...Neurobiological Technologies, Inc., +1-510-595-6000; or...Schneider, VP - Investor Relations of Porter, Le Vay & Rose, Inc., +1-212-564-4700, for...
Neurobiological Technologies Inc. to Present at the Needham 5th Annual Biotechnology & Medical Technology Conference in New York on June 14, 2006.
PR Newswire; 6/7/2006; 712 words; ...Neurobiological Technologies, Inc. NTI is a drug development company...Neurobiological Technologies, Inc., +1-510-595-6000; or...Schneider, VP - Investor Relations of Porter, Le Vay & Rose, Inc., +1-212-564-4700, for...
Neurobiological Technologies Inc. to Present at the Friedman Billings Ramsey 2006 Growth Investor Conference.
PR Newswire; 5/25/2006; 574 words; ...Neurobiological Technologies, Inc. NTI is a drug development company...Neurobiological Technologies, Inc., +1-510-595-6000; or...VP - Investor Relations, of Porter, Le Vay & Rose, Inc., +1-212-564-4700, for...
Neurobiological Technologies Inc. to Present at the Rodman & Renshaw 3rd Annual Global Healthcare Conference.
PR Newswire; 5/9/2006; 611 words; ...Neurobiological Technologies, Inc. NTI is a drug development company...Neurobiological Technologies, Inc., +1-510-595-6000; or...Schneider, VP - Investor Relations of Porter, Le Vay & Rose, Inc., +1-212-564-4700, for...
Neurobiological Technologies Inc. Announces Initiation of First Clinical Site Outside the United States for Phase III Clinical Trials for Viprinex(TM) (Ancrod).
PR Newswire; 5/4/2006; 825 words; ...Neurobiological Technologies, Inc. NTI (http://www.ntii...Neurobiological Technologies, Inc., +1-510-595-6000; or...Schneider, VP - Investor Relations of Porter, Le Vay & Rose, Inc., +1-212-564-4700, for...
Recent News Articles
- Dejour Retains Porter, LeVay & Rose, Inc.
Business Wire - September 22, 2008 - FirstFlight, Inc. Retains Porter, LeVay & Rose, Inc. as Investor Relations Counsel.
Business Wire - February 05, 2008 - OncoVista, Inc. Retains Porter, LeVay & Rose, Inc. as Investor Relations Counsel.
Business Wire - December 05, 2007 - White Energy Company Limited Retains Porter, LeVay & Rose, Inc. as Investor Relations Counsel.
Business Wire - October 30, 2007
Why Purchase This Company Profile?
- Sales prospecting
- Competitive analysis
- Vendor & supplier evaluation
- Customer evaluation and analysis
- Strategic planning